02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
19:05 , Aug 10, 2018 |  BC Week In Review  |  Company News

Zepatier lands co-exclusive status on Express Scripts 2019 formulary

Express Scripts Holding Co. (NASDAQ:ESRX) announced its 2019 National Preferred Formulary Exclusions , noting that the exclusions were driven not only by the size of the rebate as in years past, but also by lower...
20:46 , Aug 7, 2018 |  BC Extra  |  Company News

Zepatier lands co-exclusive status on Express Scripts 2019 formulary

Express Scripts Holding Co. (NASDAQ:ESRX) announced its 2019 National Preferred Formulary Exclusions , noting that the exclusions were driven not only by the size of the rebate as in years past, but also by lower...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
21:34 , Feb 24, 2017 |  BC Week In Review  |  Clinical News

Elpida: Ph IIb data

Top-line data from 102 HIV-infected patients naïve to prior antiretroviral therapy and with baseline HIV-1 RNA plasma levels of 4.7-4.8 log10 copies/ml in a double-blind, placebo-controlled, Russian Phase IIb trial showed that once-daily 20 mg...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

Tenofovir alafenamide fumarate: Phase III data

Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif.   Product: Tenofovir alafenamide fumarate (TAF)/elvitegravir/cobicistat/emtricitabine (formerly GS-7340/elvitegravir/cobicistat/emtricitabine )   Business: Infectious   Molecular target: NA   Description: Co-formulated single-tablet regimen of tenofovir alafenamide fumarate (TAF), a prodrug...
07:00 , Aug 6, 2015 |  BC Innovations  |  Targets & Mechanisms

Rethinking the reservoir

It's time to rethink using "shock and kill" in HIV - a strategy that has made no serious progress in the last 16 years towards its goal of getting patients permanently off antiretroviral therapy (ART)...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

Sustiva efavirenz regulatory update

EMA’s CHMP recommended approval of an expanded label for Merck’s Sustiva efavirenz to treat HIV-1 infection to include patients 3 months to 3 years old and weighing >=3.5 kg. The non-nucleoside reverse transcriptase inhibitor (NNRTI)...